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Abstract
Background: The surgical management of giant hepatocellular carcinoma (G-HCC), or HCC of ≥10 cm
in diameter, remains controversial. The aim of this study was to compare the outcomes of surgical resec-
tion of, respectively, G-HCC and small HCC (S-HCC), or HCC measuring <10 cm.
Methods: A retrospective review of all patients (n = 86) diagnosed with HCC and submitted to resec-
tion in a tertiary hospital during the period from January 2007 to June 2012 was conducted. Overall
survival (OS), recurrence rates and perioperative mortality at 30 days were compared between patients
with, respectively, G-HCC and S-HCC. Prognostic factors for OS were analysed.
Results: The sample included 23 patients with G-HCC (26.7%) and 63 with S-HCC (73.3%) based on
histological tumour size. Patient demographics and comorbidities were comparable. Median OS was
39.0 months in patients with G-HCC and 65.0 months in patients with S-HCC (P = 0.213). Although
size did not affect OS in this cohort, the presence of satellite lesions [hazard ratio (HR) 3.70,
P = 0.012] and perioperative blood transfusion (HR 2.85, P = 0.015) were negative predictors for OS.
Conclusions: Surgical resection of G-HCC provides OS comparable with that after resection of
S-HCC.
Received 24 March 2015; accepted 19 June 2015
Correspondence
Alfred W. C. Kow, Department of General Surgery, National University Hospital, 5 Lower Kent Ridge Road,
Singapore 119074, Singapore. Tel.: + 65 6772 3150. Fax: + 65 6777 8427. E-mail: Alfred_kow@nuhs.edu.sg
Introduction
Hepatocellular carcinoma (HCC) is one of the most common
cancers in Southeast Asia.1 For patients with HCCs of <5 cm
in diameter, surgery or transplant has been established as the
first line of treatment. However, the treatment of giant HCCs
(G-HCCs) of ≥10 cm in diameter is more controversial and
different centres advocate different modalities of treatment. In
patients with HCC, lesions of ≥10 cm are often deemed to be
non-amenable to surgery because they indicate an unfavourable
prognosis in which morbidity rates range from 25% to 50%
and mortality rates from 0% to 8%.2–4 Conflicting data have
emerged from several individual centres,5,6 suggesting that
tumour size is not critical and that physiological parameters
and the characteristics of the liver remnant are the main deter-
minants of treatment outcomes.
These controversies exist because data on the management
of G-HCC are limited. As surgery is the only viable modality
of cure in patients with G-HCC, it is essential that further
clarification of the role of surgery in these patients is
obtained.
The aims of this study were to compare survival after the
surgical resection of G-HCC and small HCC (S-HCC), respec-
tively, and to evaluate the prognostic factors influencing
outcomes in these patients.
Materials and methods
Patient selection
A retrospective review of patients who underwent surgical
resection of HCC was performed at the National University
Hospital, Singapore, a tertiary health care institution. All
patients (n = 86) who underwent liver resection for histologi-
cally proven HCC between January 2007 and June 2012 were
included. Patients were divided into two categories according
to whether they exhibited G-HCC (≥10 cm) or S-HCC
(<10 cm) based on the size of tumour detailed in the
pathology report. Patients who underwent ablative therapies
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such as radiofrequency ablation (RFA) or percutaneous ethanol
injection as the only treatment were excluded from this study.
Preoperative assessment
All patients underwent routine preoperative investigations (full
blood count, electrolytes panel, liver function test, viral serol-
ogy testing, chest X-ray and electrocardiography) prior to
operation. Triphasic computed tomography (CT) of the liver
and alpha-fetoprotein (AFP) levels were used to help make the
preoperative diagnosis and to assess the extent of the primary
tumour. For lesions that did not have typical CT features, liver
magnetic resonance imaging (MRI) was performed. Hepatic
reserve was assessed using the Child–Pugh classification.7 Indo-
cyanine green (ICG) clearance was used when remnant liver
function was equivocal. Retention of <15% ICG at 15 min was
considered adequate for major liver resection.8 Routine biopsy
of liver lesions were not performed if the lesion had typical
features of HCC on radiological imaging and biochemistry
analysis.9
Surgical technique
The extent of resection was classified according to the Brisbane
2000 Guidelines for Liver Anatomy and Resection.10 The abdo-
men was entered through a Kocher’s or rooftop incision.
Tumour visualization was achieved with intraoperative ultra-
sound with subsequent mobilization of the liver. When con-
ventional mobilization was not feasible, an anterior approach11
or liver hanging maneuvre12 was performed. Blood loss was
minimized by using Pringle’s manoeuvre or by hemihepatic
vascular inflow occlusion while maintaining a low13 central
venous pressure during parenchymal transection. Parenchymal
transection was performed with the Cavitron Ultrasonic Surgi-
cal Aspirator (CUSA; Valleylab, Inc., Boulder, CO, USA) or
LigaSure (Covidien, Inc., Mansfield, MA, USA). Concomitant
RFA was performed if there were small contralateral lesions.
Follow-up
Postoperative mortality was defined as death within 30 days of
surgery. Postoperative surveillance included a clinical examina-
tion and monitoring of the liver function panel and AFP level
at intervals of 3 months during the first year and 6 months
thereafter. Surveillance CT scans were also performed at inter-
vals of 3 months in the first year and 6 months in the second
year. Telephone interviews and a review of outpatient clinical
notes were used to determine longterm outcomes to April
2015.
Histopathological assessment was performed for both the
tumour and liver parenchyma. Tumour size was recorded
based on gross pathological examination. Surgical margins
were considered positive if viable tumour cells were seen
within 1 mm on microscopy. Tumours were graded according
to the degree of differentiation. Cirrhosis was diagnosed histo-
logically.
The primary endpoint was overall survival (OS). Secondary
endpoints were rate of recurrence and perioperative mortality
at 30 days. Prognostic factors in the surgical resection of HCC
were classified as either positive or negative prognostic factors
for OS.
Statistical analysis
Institutional review board approval was obtained from the
National University of Singapore Ethics Committee. SPSS Statis-
tics for Windows Version 17.0 (SPSS, Inc., Chicago, IL, USA)
was used for data analysis. Categorical and continuous data
were analysed using Fisher’s exact test and the Mann–Whitney
U-test, respectively. Kaplan–Meier analysis was used to depict
OS in the different study groups. Factors found to be signifi-
cant on univariate analysis for OS were subjected to multivari-
ate analysis using a Cox proportional hazard model to
determine the factors of significant prognostic value. A P-value
of <0.05 was considered to indicate statistical significance.
Results
Clinical and histopathological data are shown in Tables 1 and
2, respectively.
In patients with G-HCC, most surgical resections were per-
formed using an open approach (n = 21, 91.3%), whereas this
approach was used less often in patients with S-HCC (n = 34,
54.0%) (P = 0.002). Surgery was performed laparoscopically in
two (8.7%) patients with G-HCC and in 29 (46.1%) patients
with S-HCC (P = 0.002). The rate of major hepatectomy was
significantly higher in the G-HCC group (n = 19, 82.6%) com-
pared with the S-HCC group (n = 20, 31.7%) (P = 0.001).
Because of the greater incidence of major resection, either or
both the liver hanging manoeuvre and anterior approach were
used more frequently in the G-HCC group (n = 11, 47.8%)
compared with the S-HCC group (n = 3, 4.8%) (P = 0.001).
The incidence of postoperative 30-day mortality in all
patients was 3.5% (n = 3). The cause of death in two patients
with G-HCC was acute renal failure. The single postoperative
mortality in the S-HCC group occurred as a result of dissemi-
nated intravascular coagulopathy secondary to sepsis. The
median duration of follow-up differed significantly between
the S-HCC group (44 months; range: 1–88 months) and the
G-HCC group (22 months; range: 1–66 months) (P = 0.046).
Eleven of 23 G-HCC patients and 25 of 63 S-HCC patients
died during follow-up. The recurrence rate in the G-HCC
group (n = 5, 21.7%) was comparable with that in the S-HCC
group (n = 21, 33.3%) (P = 0.441). Median OS was
39.0 months (range: 1–66 months) in the G-HCC group and
65.0 months (range: 1–88 months) in the S-HCC group
(P = 0.213) (Fig. 1).
Univariate and multivariate analyses of the prognostic
factors influencing OS are shown in Table 3.
HPB 2015, 17, 988–993 ª 2015 International Hepato-Pancreato-Biliary Association
HPB 989
Discussion
This study analysed whether the size of the primary HCC
determines survival- and recurrence-related outcomes after sur-
gical resection. Traditionally, patients with G-HCC were often
deemed to be poor candidates for surgery2 and locoregional
therapy such as transarterial chemoembolization (TACE) was
recommended as the modality of choice.14,15 The present
authors hypothesize that the outcomes of resection will be sim-
ilar in G-HCC and S-HCC and believe that surgery is the sole
modality for cure in G-HCC. Hence, it is crucial to evaluate
surgical outcomes in these patients in order to establish
whether surgery is justified.
This study shows that the survival outcome of surgical resec-
tion of G-HCC is comparable with the outcome of surgical
resection of S-HCC, despite the fact that significantly more
major hepatectomies were performed in the G-HCC group
(82.6% versus 31.7%; P < 0.001). Factors affecting OS included
the presence of satellite lesions and need for perioperative
blood transfusions. Tumour size was not a determinant of OS.
These findings are similar to those of other reported series16,17
and strongly suggest that curative surgery is a viable option for
patients with G-HCC. In this study, the median OS in patients
submitted to resection of G-HCC was 39.0 months. Other
studies have reported median survival post-resection of HCC
of ≥10 cm of 30–32 months.18–20 In addition, similarly to
other reports by Liau et al.20 and Pawlik et al.,21 the current
study showed comparable 30-day mortality rates of 8.7% post-
resection of G-HCC. These results suggest that surgery should
be considered as a first-line therapy in the treatment of
G-HCC whenever possible as it can be performed safely and
provides for excellent OS in patients in whom only palliative
treatment would otherwise be considered.
Table 1 Demographic and clinical data for patients with,
respectively, giant (G-HCC) and small (S-HCC) hepatocellular
carcinoma
S-HCC G-HCC P-value
Patients, n 63 23
Age, years,
median (range)
59 (27–81) 63 (34–84) 0.031
Gender, n (%)
Male 50 (79.4%) 20 (87.0%) 0.541
Female 13 (20.6%) 3 (13.0%)
Underlying aetiology, n (%)
HBV 44 (69.8%) 10 (43.5%) 0.227
HCV 5 (7.9%) 1 (4.3%)
Alcoholic 3 (4.8%) 0
Cryptogenic 0 1 (4.3%)
Alcohol and HBV 0 1 (4.3%)
HBV and HCV 2 (3.2%) 0
NASH 1 (1.6%) 0
Comorbidities, n (%)
Hypertension 25 (39.7%) 14 (60.9%) 0.093
Diabetes mellitus 20 (31.7%) 5 (21.7%) 0.431
Hyperlipidaemia 13 (20.6%) 8 (34.8%) 0.256
Cerebrovascular
attacks
4 (6.3%) 0 0.570
Cardiac abnormalities 3 (4.8%) 1 (4.3%) NA
Renal disease 2 (3.2%) 1 (4.3%) NA
Pulmonary disease 1 (1.6%) 3 (13.0%) 0.057
Previous abdominal surgery, n (%)
Yes 12 (19.0%) 3 (13.0%) 0.750
No 51 (81.0%) 20 (87.0%)
Preoperative treatment, n (%)
TACE 10 (15.9%) 5 (21.7%) 0.661
RFA 1 (1.6%) 0
None 52 (82.5%) 18 (78.3%)
Presentation of disease, n (%)
Screening 39 (61.9%) 5 (21.7%) 0.005
Abdominal pain 10 (15.9%) 6 (26.1%) 0.213
Abdominal mass 11 (17.5%) 16 (69.6%) <0.001
Abdominal
distension
5 (7.9%) 3 (13.0%) 0.406
Jaundice 1 (1.6%) 0 NA
Haematemesis 1 (1.6%) 1 (4.3%) 0.440
Incidental finding 9 (14.3%) 5 (21.7%) 0.324
Liver biopsy performed, n (%)
Yes 7 (11.1%) 1 (4.3%) 0.676
No 56 (88.9%) 22 (95.7%)
Table 1 Continued
S-HCC G-HCC P-value
BCLC score, n (%)
A1 24 (38.1%) 0 <0.001
A2 9 (14.3%) 0
A3 2 (3.2%) 1 (4.3%)
A4 3 (4.8%) 1 (4.3%)
B 24 (38.1%) 19 (82.6%)
C 1 (1.6%) 2 (8.7%)
Child–Pugh class, n (%)
A 60 (95.2%) 20 (87.0%) 0.336
B 3 (4.8%) 3 (13.0%)
P-values in bold indicate differences of statistical significance at
P < 0.05.
BCLC, Barcelona Clinic Liver Cancer Group; HBV, hepatitis B virus;
HCV, hepatitis C virus; NA, not applicable; NASH, non-alcoholic
steatohepatitis; RFA, radiofrequency ablation; TACE, transarterial
chemoembolization.
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The current study revealed that the presence of satellite
lesions was an independent variable predicting poor OS. The
presence of satellite nodules has been shown in previous
studies16,22,23 to adversely affect OS as it suggests multicentric
carcinogenesis or intrahepatic metastasis. In addition, the find-
ing that perioperative blood transfusion is an independent
prognostic factor in OS is consistent with various other stud-
ies,19,20,24 including that by Asahara et al., 25 who reported that
patients who received perioperative blood transfusions were up
to 7.61 times more likely to experience tumour recurrence
compared with patients who did not receive perioperative
blood transfusions, and that these patients had a significantly
reduced rate of 5-year OS of 27.9% compared with 45.9% in
the non-transfused group. It has been postulated that the
immunomodulating effects of blood transfusions lead to
increased HCC recurrence and hence shorter OS.25 However,
need for blood transfusion may also reflect a sicker patient or
a more extensive tumour and may not be the direct cause of
poorer outcomes.
Several studies have shown microvascular invasion to be a
significant prognostic factor in OS.15,26,27 In this study,
microvascular invasion was found to represent a significant
factor in univariate analysis for OS, but was not significant
on multivariate analysis. The present authors believe that, in
a larger sample size, microvascular invasion might have been
identified as a significant prognostic factor on multivariate
analysis.
Although many studies have shown cirrhosis to be an
important negative prognostic factor,16,22,28 the present study
did not identify liver cirrhosis as adversely affecting the sur-
vival of patients with HCC. There were significantly fewer
Table 2 Histopathological data for patients with, respectively,
giant (G-HCC) and small (S-HCC) hepatocellular carcinoma
S-HCC
n (%)
G-HCC
n (%)
P-value
Patients, n 63 23
Gross vascular invasion
(n = 62) (n = 23)
Yes 4 (6.5%) 0 0.570
No 58 (93.5%) 23 (100%)
Microvascular invasion
(n = 62) (n = 23)
Yes 13 (21.0%) 11 (47.8%) 0.028
No 49 (79.0%) 12 (52.2%)
Perineural invasion
(n = 62) (n = 23)
Yes 2 (3.2%) 0 1.000
No 60 (96.8%) 23 (100%)
Lymphoinvasion
(n = 62) (n = 23)
Yes 11 (17.7%) 9 (39.1%) 0.048
No 51 (82.3%) 14 (60.9%)
Presence of tumour capsule
(n = 63) (n = 23)
Yes 37 (58.7%) 18 (78.3%) 0.129
No 26 (41.3%) 5 (21.7%)
Tumour capsule invasion
(n = 36) (n = 18)
Yes 11 (30.6%) 3 (16.7%) 0.339
No 25 (69.4%) 15 (83.3%)
Presence of satellite lesions
(n = 62) (n = 23)
Yes 12 (19.4%) 5 (21.7%) 0.770
No 50 (80.6%) 18 (78.3%)
Presence of tumour rupture
(n = 61) (n = 23)
Yes 6 (9.8%) 2 (8.7%) 1.00
No 55 (90.2%) 21 (91.3%)
Margins involved
(n = 61) (n = 23)
Yes 1 (1.6%) 3 (13.0%) 0.061
No 60 (98.4%) 20 (87.0%)
Presence of liver cirrhosis
(n = 63) (n = 23)
Yes 32 (50.8%) 3 (13.0%) 0.002
No 31 (49.2%) 20 (87.0%)
P-values in bold indicate differences of statistical significance at
P < 0.05.
Figure 1 Overall survival in patients submitted to resection of
hepatocellular carcinoma (HCC), showing comparisons between
subgroups of patients with giant HCC (G-HCC) and small HCC
(S-HCC), respectively
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patients with cirrhosis in the G-HCC group, which may reflect
an inherent characteristic of presentation and selection bias in
patients with G-HCC. Patients with cirrhosis are often under
regular surveillance and thus any HCC that develops in the cir-
rhotic liver is often detected when it is still relatively small.
Patients with significant liver cirrhosis who develop HCC of
>10 cm are very unlikely to be resectable as the remnant liver
function is likely to be inadequate after major liver resection.
Although techniques such as portal vein embolization29 and
the associating of liver partition with portal vein ligation for
staged hepatectomy30 may increase the chances of resectability,
the regenerative potential of a cirrhotic liver is often unpre-
dictable and is quite certainly inferior to that of a non-cir-
rhotic liver. The present study showed that patients with G-
HCC were less likely to have liver cirrhosis. In fat, their disease
was more likely to present in the form of an abdominal mass
or to be picked up incidentally on scans. These factors may
explain why longterm outcomes in G-HCC patients were com-
parable with those in S-HCC patients.
This study was limited by the low number of patients who
underwent resection of G-HCC. Overall survival was signifi-
cantly better than rates reported in other similar stud-
ies,16,18,19 although this may be secondary to the limited
sample size and compounded by the selection of patients with
better hepatic reserves for surgery. However, this limitation
will have been inherent in similar papers as a result of the
small number of G-HCC patients submitted to hepatic resec-
tion.
In conclusion, this study shows that tumour size does not
influence surgical outcomes in resection of HCC.
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